{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:38:14Z","timestamp":1792219094298,"version":"4.4.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NCI R01 CA223231"],"award-info":[{"award-number":["NCI R01 CA223231"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U2C CA233303"],"award-info":[{"award-number":["U2C CA233303"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.semnephrol.2019.12.004","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T18:59:29Z","timestamp":1582570769000},"page":"28-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age"],"prefix":"10.1016","volume":"40","author":[{"given":"Jennifer J.","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2019.12.004_bib0001","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0002","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1042\/bss0700147","article-title":"Proteases as drug targets","volume":"70","author":"Docherty","year":"2003","journal-title":"Biochem Soc Symp"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0003","unstructured":"SEER Cancer Statistics Review, 1975-2016. National Cancer Institute. [cited 2019 August 5]. Available from:https:\/\/seer.cancer.gov\/csr\/1975_2016\/."},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0004","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0094-0143(03)00056-9","article-title":"Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease","volume":"30","author":"Janzen","year":"2003","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0005","first-page":"1","article-title":"Surveillance strategies for renal cell carcinoma patients following nephrectomy","volume":"8","author":"Chin","year":"2006","journal-title":"Rev Urol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0006","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1200\/JCO.2018.79.0147","article-title":"Prognostication in kidney cancer: recent advances and future directions","volume":"6","author":"Graham","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0007","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0008","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1056\/NEJMcp0910041","article-title":"Clinical practice. Small renal mass","volume":"362","author":"Gill","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0009","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0010","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41585-019-0211-5","article-title":"The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications","volume":"16","author":"Linehan","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0011","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1200\/JCO.2018.79.2549","article-title":"Chromosome 3p loss-orchestrated VHL, HIF, and epigenetic deregulation in clear cell renal cell carcinoma","volume":"36","author":"Hsieh","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0012","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/ng.2708","article-title":"A clear picture of renal cell carcinoma","volume":"45","author":"Hakimi","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0013","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s13059-014-0433-z","article-title":"Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution","volume":"15","author":"Fisher","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0014","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0015","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nrc2502","article-title":"The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer","volume":"8","author":"Kaelin","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0016","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von Hippel-Lindau disease tumor suppressor gene","volume":"260","author":"Latif","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0017","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1200\/JCO.2018.79.2259","article-title":"Renal cell carcinoma in the era of precision medicine: from molecular pathology to tissue-based biomarkers","volume":"36","author":"Signoretti","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0018","doi-asserted-by":"crossref","first-page":"E967","DOI":"10.1016\/j.juro.2016.02.1672","article-title":"Single-institutional analysis of patients with clear-cell papillary renal cell carcinoma","volume":"195","author":"Casuscelli","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0019","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41467-017-00289-x","article-title":"Pan-urologic cancer genomic subtypes that transcend tissue of origin","volume":"8","author":"Chen","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2016.10.007","article-title":"Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma","volume":"71","author":"Hsieh","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0021","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive molecular characterization of papillary renal-cell carcinoma","volume":"374","author":"Linehan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0022","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/KCA-170008","article-title":"Molecular classification of renal cell carcinoma and its implication in future clinical practice","volume":"1","author":"Casuscelli","year":"2017","journal-title":"Kidney Cancer"},{"issue":"12","key":"10.1016\/j.semnephrol.2019.12.004_bib0023","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92688","article-title":"Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma","volume":"2","author":"Casuscelli","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0024","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/path.5022","article-title":"Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision","volume":"244","author":"Hsieh","year":"2018","journal-title":"J Pathol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0025","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.eururo.2019.02.011","article-title":"European Association of Urology guidelines on renal cell carcinoma: the 2019 update","volume":"75","author":"Ljungberg","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0026","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-0033-1363840","article-title":"Surgical management of renal cell carcinoma","volume":"31","author":"Krabbe","year":"2014","journal-title":"Semin Intervent Radiol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0027","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/14737140.2018.1469980","article-title":"Adjuvant therapy for advanced renal cell carcinoma","volume":"18","author":"Meissner","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0028","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0029","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/cncr.25836","article-title":"Survival after complete surgical resection of multiple metastases from renal cell carcinoma","volume":"117","author":"Alt","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0030","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrurol.2017.87","article-title":"Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach","volume":"14","author":"Siva","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0031","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0360-3016(95)02029-2","article-title":"A review of human cell radiosensitivity in vitro","volume":"34","author":"Deschavanne","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0032","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1016\/S1470-2045(13)70569-2","article-title":"Radiotherapy for renal-cell carcinoma","volume":"15","author":"De Meerleer","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0033","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1055\/s-0033-1363847","article-title":"Role of radiation therapy for renal tumors","volume":"31","author":"Parashar","year":"2014","journal-title":"Semin Intervent Radiol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0034","first-page":"7310","article-title":"Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma","volume":"48","author":"Elson","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0035","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0094-0143(21)00489-4","article-title":"Cytotoxic chemotherapy for advanced renal cell carcinoma","volume":"20","author":"Yagoda","year":"1993","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0036","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00195367","article-title":"Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma","volume":"6","author":"Elson","year":"1988","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0037","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/0360-3016(86)90182-3","article-title":"Phase II trial of misonidazole (MISO) and cyclophosphamide (CYC) in metastatic renal cell carcinoma","volume":"12","author":"Glover","year":"1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0038","first-page":"187","article-title":"Interferon in metastatic renal cell carcinoma","volume":"27","author":"Fossa","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0039","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1163462","article-title":"Role of IL-2 in cancer immunotherapy","volume":"5","author":"Jiang","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0040","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0041","first-page":"7","article-title":"A review of renal cell carcinoma","volume":"32","author":"Pace MaC","year":"2007","journal-title":"US Pharm"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0042","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cncr.23552","article-title":"High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006","volume":"113","author":"Klapper","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0043","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJM199609193351207","article-title":"Renal-cell carcinoma","volume":"335","author":"Motzer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0044","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0045","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198704093161501","article-title":"A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone","volume":"316","author":"Rosenberg","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0046","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0047","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1359-6101(01)00022-3","article-title":"Interferon-alpha in tumor immunity and immunotherapy","volume":"13","author":"Belardelli","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0048","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0049","article-title":"Immunotherapy for advanced renal cell cancer","volume":"1","author":"Coppin","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0050","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1016\/j.celrep.2017.02.074","article-title":"The SWI\/SNF protein PBRM1 restrains VHL-loss-driven clear cell renal cell carcinoma","volume":"18","author":"Nargund","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0051","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2174\/156800912802429265","article-title":"A comprehensive overview of targeted therapy in metastatic renal cell carcinoma","volume":"12","author":"Mihaly","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0052","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2018.79.2648","article-title":"The immunobiology of kidney cancer","volume":"36","author":"Drake","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0053","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0054","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0055","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1200\/JCO.2008.19.3342","article-title":"Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0056","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0057","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0058","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0059","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0060","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0061","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0062","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.clinthera.2012.01.014","article-title":"Pazopanib for the treatment of metastatic renal cell carcinoma","volume":"34","author":"Pick","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0063","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0064","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJMc1400731","article-title":"Overall survival in renal-cell carcinoma with pazopanib versus sunitinib","volume":"370","author":"Motzer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0065","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study","volume":"32","author":"Escudier","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0066","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(07)70285-1","article-title":"Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study","volume":"8","author":"Rixe","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0067","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2008.21.7034","article-title":"Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma","volume":"27","author":"Rini","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0068","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S1470-2045(13)70464-9","article-title":"Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial","volume":"14","author":"Rini","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0069","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.hoc.2011.04.008","article-title":"mTOR inhibitors in advanced renal cell carcinoma","volume":"25","author":"Voss","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0070","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2217\/thy.11.32","article-title":"mTOR inhibitors in renal cell carcinoma","volume":"8","author":"Battelli","year":"2011","journal-title":"Therapy"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0071","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0072","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1200\/JCO.2013.50.3961","article-title":"Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma","volume":"32","author":"Hutson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0073","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0074","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdx075","article-title":"Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC","volume":"28","author":"Knox","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0075","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","article-title":"CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients","volume":"19","author":"Ott","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0076","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1073\/pnas.0830997100","article-title":"Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients","volume":"100","author":"Hodi","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0077","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0078","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1158\/1078-0432.CCR-14-1993","article-title":"Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial","volume":"21","author":"Choueiri","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0079","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-06-2599","article-title":"PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma","volume":"13","author":"Thompson","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0080","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0081","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(18)30778-2","article-title":"Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial","volume":"20","author":"Cella","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0082","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0083","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0084","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semnephrol.2019.12.004_bib0085","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929519301147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929519301147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T21:44:50Z","timestamp":1778535890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929519301147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0270929519301147"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2019.12.004","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2019.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}